Grifols (GRFS) Competitors $9.32 -0.17 (-1.79%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$9.32 0.00 (0.00%) As of 10/10/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRFS vs. BNTX, TEVA, GMAB, SMMT, ASND, VTRS, RDY, MRNA, ROIV, and QGENShould you be buying Grifols stock or one of its competitors? The main competitors of Grifols include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Roivant Sciences (ROIV), and QIAGEN (QGEN). These companies are all part of the "pharmaceutical products" industry. Grifols vs. Its Competitors BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Moderna Roivant Sciences QIAGEN Grifols (NASDAQ:GRFS) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends. Do analysts rate GRFS or BNTX? Grifols presently has a consensus price target of $10.30, suggesting a potential upside of 10.52%. BioNTech has a consensus price target of $134.32, suggesting a potential upside of 31.61%. Given BioNTech's stronger consensus rating and higher probable upside, analysts plainly believe BioNTech is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50BioNTech 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.64 Is GRFS or BNTX more profitable? Grifols has a net margin of 0.00% compared to BioNTech's net margin of -12.20%. Grifols' return on equity of 0.00% beat BioNTech's return on equity.Company Net Margins Return on Equity Return on Assets GrifolsN/A N/A N/A BioNTech -12.20%-1.84%-1.59% Which has stronger valuation and earnings, GRFS or BNTX? Grifols has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$7.81B0.82$169.80M$1.177.97BioNTech$2.98B8.24-$719.92M-$1.60-63.79 Does the media favor GRFS or BNTX? In the previous week, BioNTech had 4 more articles in the media than Grifols. MarketBeat recorded 10 mentions for BioNTech and 6 mentions for Grifols. BioNTech's average media sentiment score of 0.79 beat Grifols' score of 0.75 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, GRFS or BNTX? Grifols has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Do institutionals and insiders have more ownership in GRFS or BNTX? 15.5% of BioNTech shares are owned by institutional investors. 0.2% of Grifols shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryBioNTech beats Grifols on 9 of the 17 factors compared between the two stocks. Get Grifols News Delivered to You Automatically Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRFS vs. The Competition Export to ExcelMetricGrifolsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.52B$2.69B$6.10B$10.61BDividend Yield1.50%56.72%5.67%4.71%P/E Ratio7.9723.2286.0526.57Price / Sales0.82738.35612.14131.72Price / Cash10.14179.8938.5062.09Price / Book0.695.3712.756.53Net Income$169.80M$32.78M$3.31B$276.43M7 Day Performance-6.33%2.01%0.80%-0.88%1 Month Performance-7.17%7.66%6.21%3.55%1 Year Performance8.50%-1.74%80.34%37.91% Grifols Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRFSGrifols3.8501 of 5 stars$9.32-1.8%$10.30+10.5%+8.0%$6.52B$7.81B7.9723,822News CoverageAnalyst ForecastBNTXBioNTech2.1433 of 5 stars$105.16-0.3%$134.56+28.0%-13.8%$25.36B$2.98B-65.726,772Analyst ForecastTEVATeva Pharmaceutical Industries3.0321 of 5 stars$19.99-0.1%$25.57+27.9%+14.9%$22.95B$16.54B-124.9436,830Analyst ForecastAnalyst RevisionGMABGenmab A/S4.1896 of 5 stars$33.31-0.7%$40.80+22.5%+34.2%$21.55B$3.12B16.742,682Analyst ForecastAnalyst RevisionHigh Trading VolumeSMMTSummit Therapeutics3.0436 of 5 stars$22.15+3.4%$31.29+41.2%+14.7%$15.92B$700K-21.93110Analyst ForecastASNDAscendis Pharma A/S3.1023 of 5 stars$210.83+3.3%$244.36+15.9%+60.8%$12.59B$393.54M-40.861,017News CoverageAnalyst ForecastHigh Trading VolumeVTRSViatris1.944 of 5 stars$10.13-0.6%$10.40+2.7%-14.0%$11.88B$14.74B-3.4932,000Positive NewsAnalyst ForecastRDYDr. Reddy's Laboratories2.6893 of 5 stars$14.12-0.3%$16.95+20.0%-7.2%$11.82B$3.81B21.3927,811Positive NewsAnalyst ForecastMRNAModerna4.239 of 5 stars$27.54-3.3%$41.81+51.8%-52.8%$11.08B$3.24B-3.665,800Analyst ForecastROIVRoivant Sciences3.4137 of 5 stars$16.26+0.6%$19.94+22.6%+35.1%$11.04B$29.05M-23.23860Analyst ForecastInsider TradeQGENQIAGEN4.2961 of 5 stars$46.99+0.4%$49.40+5.1%+11.5%$10.40B$1.98B27.765,765News CoverageAnalyst Forecast Related Companies and Tools Related Companies BNTX Alternatives TEVA Alternatives GMAB Alternatives SMMT Alternatives ASND Alternatives VTRS Alternatives RDY Alternatives MRNA Alternatives ROIV Alternatives QGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRFS) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grifols, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grifols With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
